Literature DB >> 9402810

Preventing stroke in atrial fibrillation.

P A Wolf1, D E Singer.   

Abstract

Atrial fibrillation, a common cardiac arrhythmia, is now recognized as a powerful risk factor for stroke. Previously, atrial fibrillation was thought to predispose persons to stroke only in the presence of rheumatic heart disease with mitral stenosis. The significant impact of nonvalvular atrial fibrillation on stroke incidence, recurrence and mortality was not fully appreciated. A series of clinical trials have confirmed that a five-fold increase in stroke incidence occurs in patients with atrial fibrillation, and that warfarin anticoagulation is efficacious in stroke prevention. This anticoagulation benefit was achieved with an acceptably low risk of serious hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402810

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  10 in total

1.  Management of atrial fibrillation. Rhythm or rate? That is the question.

Authors:  Sharon K Bal; Charles Czarnowski
Journal:  Can Fam Physician       Date:  2003-11       Impact factor: 3.275

2.  Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.

Authors:  J B Segal; R L McNamara; M R Miller; N Kim; S N Goodman; N R Powe; K A Robinson; E B Bass
Journal:  J Gen Intern Med       Date:  2000-01       Impact factor: 5.128

3.  New treatment options for stroke prevention in atrial fibrillation.

Authors:  Benjamin Rhee; Richard L Page
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-10

4.  Strategies for Risk Analysis and Disease Classification in Atrial Fibrillation.

Authors:  Sara Adelman; Georges Daoud; Peter J Mohler
Journal:  J Cardiovasc Electrophysiol       Date:  2016-09-20

5.  Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.

Authors:  Patrick P Kneeland; Margaret C Fang
Journal:  Patient Prefer Adherence       Date:  2010-03-24       Impact factor: 2.711

Review 6.  Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation.

Authors:  Mark H Eckman
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

7.  Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare.

Authors:  Melina Gattellari; Dominic Y Leung; Obioha C Ukoumunne; Nicholas Zwar; Jeremy Grimshaw; John M Worthington
Journal:  Implement Sci       Date:  2011-05-20       Impact factor: 7.327

8.  Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography.

Authors:  Xiao Fei Xing; Nan Nan Liu; Ya Ling Han; Wei Wei Zhou; Ming Liang; Zu Lu Wang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

9.  The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey.

Authors:  Melina Gattellari; John M Worthington; Nicholas A Zwar; Sandy Middleton
Journal:  BMC Fam Pract       Date:  2008-11-13       Impact factor: 2.497

Review 10.  Genetic basis of atrial fibrillation.

Authors:  Oscar Campuzano; Alexandra Perez-Serra; Anna Iglesias; Ramon Brugada
Journal:  Genes Dis       Date:  2016-09-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.